Tag Archives: Abbott

Abbott Acknowledges Libre 2 Delay; Abbott and Roche Q3 ’19 Earnings Updates

Abbott and Roche hosted their respective Q3 ’19 earnings calls and provided updates to their diabetes businesses. Of note, Abbott confirmed that Libre 2 US approval is delayed from initial expectations, and Abbott indicated they are working through several items with FDA. Below, FENIX provides highlights and insights from the respective calls.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott and Tandem partnership; Livongo partners with VSP Vision Care

Abbott and Tandem Diabetes Care announced plans to develop an integrated diabetes solution utilizing Abbott’s glucose monitoring sensors (Libre) and Tandem’s insulin delivery systems. Additionally, Livongo and VSP Vision Care announced a partnership to expand eye care outreach efforts to Livongo members with diabetes. Below, FENIX provides context and broader implications on these partnerships.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott Partners with Omada; New Senseonics BCBS Coverage; Adocia Receives €15M in Funding; Roche Partners with iHeartMedia

Today, three major news items were observed covering a new partnership between Abbott and Omada Health, Senseonics Eversense new BCBS coverage decision, €15 million in financing for Adocia, and a Roche/iHeartMedia diabetes awareness concert. Below, FENIX provides thoughts and analysis for each respective news item.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott Libre 2 US Approval Conspicuously Late?

The FDA approval of Abbott’s next-generation CGM, Libre 2, appears to be conspicuously late, which has created questions as to what the potential issue could be. Below, FENIX provides evidence and hypotheses surrounding the delayed Libre 2 US approval. See the full blast for more details on our 3 hypotheses.

This content is for Read Less members only.
Register

Already a member? Log in here

Farxiga HF Fast Track Designation; New Novo/Medtronic and Sanofi/Abbott Partnerships

With the start of the 2019 EASD conference, a series of diabetes drug and device-related press releases have been observed including connected care partnerships between Novo/Medtronic and Sanofi/Abbott. Additionally, AstraZeneca announced that FDA granted Fast Track designation for dapagliflozin in worsening heart failure. Below FENIX insights and context from each respective announcement.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott Q2 ’19 Earnings Update

Abbott hosted its Q2 ’19 earnings call and provided updates to its FreeStyle Libre commercial performance and LCM initiatives. Curiously, Abbott did not provide an update on the number of global Libre users which it had been consistently disclosing over recent quarters. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Register

Already a member? Log in here